This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

Pramipexole

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Pramipexole is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS).[1][2][3] Pramipexole is also sold under the brand names Mirapex and Mirapex ER.[3]

Theory[edit | edit source]

Evidence[edit | edit source]

No clinicial trials have yet been carried out of pramipexole for patients with ME/CFS.

In 2005, Holman et al. found that pramipexole improved fatigue, pain, and overall function in fibromyalgia patients.[4]

Pramipexole has been shown to reduce fatigue in Parkinson's disease.[5]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Notable studies[edit | edit source]

  • 2005, A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications[4] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Pramipexole". MedlinePlus Drug Information. Retrieved February 21, 2022.
  2. Singh, Raman; Parmar, Mayur (2022). Pramipexole. Treasure Island (FL): StatPearls Publishing. PMID 32491471.
  3. Jump up to: 3.0 3.1 "Pramipexole Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". WebMD. Retrieved February 21, 2022.
  4. Jump up to: 4.0 4.1 Holman, Andrew J.; Myers, Robin R. (2005). "A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications". Arthritis & Rheumatism. 52 (8): 2495–2505. doi:10.1002/art.21191. ISSN 1529-0131.
  5. https://www.jstage.jst.go.jp/article/internalmedicine/50/19/50_19_2163/_article/-char/ja/